Abstract
Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.
Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.
Reviews on Recent Clinical Trials
Title:Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review
Volume: 9 Issue: 1
Author(s): Tolia Maria, Zygogianni Anna, Kouvaris John R., Tsoukalas Nikolaos, Kokakis Ioannis, Kyrgias George, Mystakidou Kyriaki and Kouloulias Vasileios
Affiliation:
Keywords: Inflammatory bowel diseases, radiotherapy, toxicity.
Abstract: Background/Aim: The evaluation of radiotherapy toxicity in oncologic IBD patients. Defining the optimal patient and treatment factors that would be able to reduce the risk to organs.
Materials and Methods: A review of all published radiotherapy trials was performed to identify the clinical and treatment factors of inflammatory bowel disease’s patients treated for different solid tumors.
Results: Overall, acute (Grade ≥ 3) gastrointestinal complications attributable to RT ranged between 20-21% of the treated patients. A late Grade ≥ 3 gastrointestinal toxicity was developed in a range between 8-29%.
Conclusion: A special attention should be given to the description of IBD location, activity status, concurrent chemotherapy, irradiation dose and technique, in order to minimize post-irradiation morbidity. It is not easy to distinguish late morbidity attributable to radiotherapy due to the IBD itself.
Export Options
About this article
Cite this article as:
Maria Tolia, Anna Zygogianni, R. John Kouvaris, Nikolaos Tsoukalas, Ioannis Kokakis, George Kyrgias, Kyriaki Mystakidou and Vasileios Kouloulias, Irradiation Toxicity and Inflammatory Bowel Diseases (IBD): Review, Reviews on Recent Clinical Trials 2014; 9 (1) . https://dx.doi.org/10.2174/1574887109666140423123845
DOI https://dx.doi.org/10.2174/1574887109666140423123845 |
Print ISSN 1574-8871 |
Publisher Name Bentham Science Publisher |
Online ISSN 1876-1038 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Medication-Induced Acute Abdominal Pain: Evaluation with CT Imaging
Current Medical Imaging Neuronal Nitric Oxide Synthase and Sympathetic Nerve Activity in Neurovascular and Metabolic Systems
Current Neurovascular Research Effects of Altered Plasminogen Activator Inhibitor-1 Expression on Cardiovascular Disease
Current Drug Targets Serpins for Diagnosis and Therapy in Cancer
Cardiovascular & Hematological Disorders-Drug Targets PCSK9 and LDLR The Yin-Yang in the Cellular Uptake of Cholesterol
Current Hypertension Reviews Antithrombotic Therapy in Cardiac Embolism
Current Cardiology Reviews Headache in Multiple Sclerosis - Pharmacological Aspects
Current Pharmaceutical Design Oxidative Stress: Meeting Multiple Targets in Pathogenesis of Diabetic Nephropathy
Current Drug Targets Role of Advanced Glycation End Products in Diabetic Neuropathy
Current Pharmaceutical Design Current Advances in Clinical Trials for Rare Disease Populations: Spotlight on the Patient
Current Reviews in Clinical and Experimental Pharmacology Crosstalk between Oxidative and Nitrosative Stress and Arterial Stiffness
Current Vascular Pharmacology Cardiovascular Disease in the Rheumatic Diseases: How Systemic Inflammation May Contribute to Atherogenesis
Current Rheumatology Reviews Adverse Dermatological Reactions in Rheumatoid Arthritis Patients Treated with Etanercept, an Anti-TNFα Drug
Current Drug Safety Pathophysiology of Myocardial Infarction and Acute Management Strategies
Cardiovascular & Hematological Agents in Medicinal Chemistry Randomized Controlled Trials in Steroid Dependent and in Severe Colitis
Reviews on Recent Clinical Trials Q Fever Endocarditis
Infectious Disorders - Drug Targets Reduction of eNOS in Vascular Smooth Muscle by Salt Independently of Hypertension
Anti-Inflammatory & Anti-Allergy Agents in Medicinal Chemistry Smoking and Atherosclerosis: Mechanisms of Disease and New Therapeutic Approaches
Current Medicinal Chemistry The Perils, Pitfalls and Opportunities of Using High Sensitivity Cardiac Troponin
Current Medicinal Chemistry An Alternative “Trojan Horse” Hypothesis for COVID-19: Immune Deficiency of IL-10 and SARS-CoV-2 Biology
Endocrine, Metabolic & Immune Disorders - Drug Targets